Biopsy proportion of tumour predicts pathological tumour response and benefit from chemotherapy in resectable oesophageal carcinoma: results from the UK MRC OE02 trial

BACKGROUND: Neoadjuvant chemotherapy followed by surgery is the standard of care for UK patients with locally advanced resectable oesophageal carcinoma (OeC). However, not all patients benefit from multimodal treatment and there is a clinical need for biomarkers which can identify chemotherapy respo...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Hale, Matthew D., Nankivell, Matthew, Hutchins, Gordon G., Stenning, Sally P., Langley, Ruth E., Mueller, Wolfram, West, Nicholas P., Wright, Alexander I., Treanor, Darren, Hewitt, Lindsay C., Allum, William H., Cunningham, David, Hayden, Jeremy D., Grabsch, Heike I.
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2016
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5363605/
https://ncbi.nlm.nih.gov/pubmed/27769054
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.12723
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars